Glomerular disease: Targeted steroid therapy for IgA nephropathy

Nature Reviews Nephrology 13, 390 (2017). doi:10.1038/nrneph.2017.65 Author: Richard J. Glassock Encouraging preliminary data from the NEFIGAN trial suggest that a novel oral formulation of budesonide might reduce disease progression in IgA nephropathy. This formulation releases corticosteroid in the distal small intestine and colon, so is thought to directly target the mucosal element of the pathogenesis of the disease.
Source: Nature Reviews Nephrology - Category: Urology & Nephrology Authors: Tags: News and Views Source Type: research